Phesgo and Tecentriq Performance and Approvals
Major pending approvals 2023
Roche
Japan-Chugai
Phesgo
HER-2+ BC/CC
Filed Sept 2022
Actemra
Cytokine release syndrome (CRS)
Filed March 2023
RG7446
RG6026
US
Tecentriq SC
Filed Nov 2022
3L+ DLBCL
EU
China
Evrysdi
Evrysdi
all approved indications
RG7916
SMA presymptomatic pediatric <2mo
RG7916
SMA presymptomatic pediatric <2mo
RG6264
Filed Nov 2021
Filed June 2022
Columvi (glofitamab)
RG6413+
RG6412
Filed Dec 2022
Ronapreve*
SARS-CoV-2 hospitalized
Filed Jan 2022
RG6264
Columvi (glofitamab)
RG6026
3L+ DLBCL
RG6107
Filed April 2022
RG1569
Actemra
SS-ILD
RG6026
Filed Aug 2022
Tecentriq SC
Phesgo
HER-2+ BC
Filed July 2022
crovalimab
PNH
Filed Aug 2022
Columvi (glofitamab)
3L+ DLBCL
Filed Dec 2022
RG1569
RG7446
all approved indications
Filed Nov 2022
Status as of April 26, 2023
New Molecular Entity (NME)
Additional Indication (Al)
Oncology/Hematology
Immunology
Infectious Diseases
Metabolism
Neuroscience
Ophthalmology
Other
SC=Subcutaneous
*Ronapreve (casirivimab+imdevimab also known as REGEN-COV in the US)
developed in collaboration with Regeneron Pharmaceuticals
57
57View entire presentation